Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients

Antiviral Research

Volumn 82, Issue 3, 2009, Pages 115-121

  Hachiya, Atsuko ^a,b   Shimane, Kazuki ^c   Sarafianos, Stefan G ^d   Kodama, Eiichi N ^c   Sakagami, Yasuko ^c   Negishi, Fujie ^a   Koizumi, Hirokazu ^b   Gatanaga, Hiroyuki ^a,b   Matsuoka, Masao ^c   Takiguchi, Masafumi ^b   Oka, Shinichi ^a,b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d University of Missouri   (United States)

Author keywords

Antiretroviral treatment na ve patient; Connection subdomain; HIV 1; Resistant mutation; RNase H domain

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 64749091545     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.02.189     Document Type: Article

References (44)

1. Abbondanzieri E.A., Bokinsky G., Rausch J.W., Zhang J.X., Le Grice S.F., and Zhuang X. Dynamic binding orientations direct activity of HIV reverse transcriptase. Nature 453 (2008) 184-189
2. Arnold E., and Sarafianos S.G. Molecular biology: an HIV secret uncovered. Nature 453 (2008) 169-170
3. Boyer P.L., Sarafianos S.G., Arnold E., and Hughes S.H. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J. Virol. 75 (2001) 4832-4842
4. Brehm J.H., Koontz D., Meteer J.D., Pathak V., Sluis-Cremer N., and Mellors J.W. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3′-azido-3′-dideoxythymidine. J. Virol. 81 (2007) 7852-7859
5. Caride E., Brindeiro R., Hertogs K., Larder B., Dehertogh P., Machado E., de Sá C.A., Eyer-Silva W.A., Sion F.S., Passioni L.F., Menezes J.A., Calazans A.R., and Tanuri A. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology 275 (2000) 107-115
6. Clark S.A., Shulman N.S., Bosch R.J., and Mellors J.W. Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. AIDS 20 (2006) 981-984
7. Cozzi-Lepri A., Ruiz L., Loveday C., Phillips A.N., Clotet B., Reiss P., Ledergerber B., Holkmann C., Staszewski S., and Lundgren J.D. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir. Ther. 10 (2005) 791-802
8. Delaugerre C., Mouroux M., Yvon-Groussin A., Simon A., Angleraud F., Huraux J.M., Agut H., Katlama C., and Calvez V. Prevalence and conditions of selection of E44D/A and V118I human immunodeficiency virus type 1 reverse transcriptase mutations in clinical practice. Antimicrob. Agents Chemother. 45 (2001) 946-948
9. Delviks-Frankenberry K.A., Nikolenko G.N., Barr R., and Pathak V.K. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3′-azido-3′-deoxythymidine resistance. J. Virol. 81 (2007) 6837-6845
10. Delviks-Frankenberry K.A., Nikolenko G.N., Boyer P.L., Hughes S.H., Coffin J.M., Jere A., and Pathak V.K. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc. Natl. Acad. Sci. USA 105 (2008) 10943-10948
11. Descamps D., Chaix M.L., André P., Brodard V., Cottalorda J., Deveau C., Harzic M., Ingrand D., Izopet J., Kohli E., Masquelier B., Mouajjah S., Palmer P., Pellegrin I., Plantier J.C., Poggi C., Rogez S., Ruffault A., Schneider V., Signori-Schmück A., Tamalet C., Wirden M., Rouzioux C., Brun-Vezinet F., Meyer L., and Costagliola D. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J. Acquir. Immune Defic. Syndr. 38 (2005) 545-552
12. Deval J., Selmi B., Boretto J., Egloff M.P., Guerreiro C., Sarfati S., and Canard B. The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues. J. Biol. Chem. 277 (2002) 42097-42104
13. Ehteshami M., Beilhartz G.L., Scarth B.J., Tchesnokov E.P., McCormick S., Wynhoven B., Harrigan P.R., and Gotte M. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3′-azido-3′-deoxythymidine through both RNase H-dependent and H-independent mechanisms. J. Biol. Chem. 283 (2008) 22222-22232
14. Gallego O., Corral A., de Mendoza C., Rodés B., and Soriano V. Prevalence of G333D/E in naive and pretreated HIV-infected patients. AIDS Res. Hum. Retroviruses 18 (2002) 857-860
15. Gatanaga H., Ibe S., Matsuda M., Yoshida S., Asagi T., Kondo M., Sadamasu K., Tsukada H., Masakane A., Mori H., Takata N., Minami R., Tateyama M., Koike T., Itoh T., Imai M., Nagashima M., Gejyo F., Ueda M., Hamaguchi M., Kojima Y., Shirasaka T., Kimura A., Yamamoto M., Fujita J., Oka S., and Sugiura W. Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan. Antiviral Res. 75 (2007) 75-82
16. Hachiya A., Aizawa-Matsuoka S., Tanaka M., Takahashi Y., Ida S., Gatanaga H., Hirabayashi Y., Kojima A., Tatsumi M., and Oka S. Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5). Antimicrob. Agents Chemother. 45 (2001) 495-501
17. Hachiya A., Kodama E.N., Sarafianos S.G., Schuckmann M.M., Sakagami Y., Matsuoka M., Takiguchi M., Gatanaga H., and Oka S. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J. Virol. 82 (2008) 3261-3270
18. Kantor R., Katzenstein D.A., Efron B., Carvalho A.P., Wynhoven B., Cane P., Clarke J., Sirivichayakul S., Soares M.A., Snoeck J., Pillay C., Rudich H., Rodrigues R., Holguin A., Ariyoshi K., Bouzas M.B., Cahn P., Sugiura W., Soriano V., Brigido L.F., Grossman Z., Morris L., Vandamme A.M., Tanuri A., Phanuphak P., Weber J.N., Pillay D., Harrigan P.R., Camacho R., Schapiro J.M., and Shafer R.W. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2 (2005) e112
19. Kemp S.D., Shi C., Bloor S., Harrigan P.R., Mellors J.W., and Larder B.A. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2′, 3′-dideoxy-3′-thiacytidine. J. Virol. 72 (1998) 5093-5098
20. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., Koup R.A., Mellors J.W., Connick E., Conway B., Kilby M., Wang L., Whitcomb J.M., Hellmann N.S., and Richman D.D. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347 (2002) 385-394
21. Maga G., Ubiali D., Salvetti R., Pregnolato M., and Spadari S. Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes. Antimicrob. Agents Chemother. 44 (2000) 1186-1194
22. Marcelin A.G., Delaugerre C., Wirden M., Viegas P., Simon A., Katlama C., and Calvez V. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J. Med. Virol. 72 (2004) 162-165
23. Meyer P.R., Matsuura S.E., Mian A.M., So A.G., and Scott W.A. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell 4 (1999) 35-43
24. Miller M.D., Margot N., Lu B., Zhong L., Chen S.S., Cheng A., and Wulfsohn M. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J. Infect. Dis. 189 (2004) 837-846
25. Montes B., Vergne L., Peeters M., Reynes J., Delaporte E., and Segondy M. Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J. Acquir. Immune Defic. Syndr. 35 (2004) 329-336
26. Motakis D., and Parniak M.A. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46 (2002) 1851-1856
27. Nikolenko G.N., Delviks-Frankenberry K.A., Palmer S., Maldarelli F., Fivash Jr. M.J., Coffin J.M., and Pathak V.K. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance. Proc. Natl. Acad. Sci. USA 104 (2007) 317-322
28. Nikolenko G.N., Palmer S., Maldarelli F., Mellors J.W., Coffin J.M., and Pathak V.K. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. USA 102 (2005) 2093-2098
29. Nikolenko G.N., Svarovskaia E.S., Delviks K.A., and Pathak V.K. Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency. J. Virol. 78 (2004) 8761-8770
30. Novitsky V., Wester C.W., DeGruttola V., Bussmann H., Gaseitsiwe S., Thomas A., Moyo S., Musonda R., Van Widenfelt E., Marlink R.G., and Essex M. The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. AIDS Res. Hum. Retroviruses 23 (2007) 868-878
31. Ntemgwa M., Wainberg M.A., Oliveira M., Moisi D., Lalonde R., Micheli V., and Brenner B.G. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob. Agents Chemother. 51 (2007) 3861-3869
32. Parkin N.T., Hellmann N.S., Whitcomb J.M., Kiss L., Chappey C., and Petropoulos C.J. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48 (2004) 437-443
33. Rhee S.Y., Taylor J., Wadhera G., Ben-Hur A., Brutlag D.L., and Shafer R.W. Genotypic predictors of human immunodeficiency virus type 1 drug resistance. Proc. Natl. Acad. Sci. USA 103 (2006) 17355-17360
34. Romano L., Venturi G., Bloor S., Harrigan R., Larder B.A., Major J.C., and Zazzi M. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118. J. Infect. Dis. 185 (2002) 898-904
35. Roquebert B., and Marcelin A.G. The involvement of HIV-1 RNase H in resistance to nucleoside analogues. J. Antimicrob. Chemother. 61 (2008) 973-975
36. Roquebert B., Wirden M., Simon A., Deval J., Katlama C., Calvez V., and Marcelin A.G. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naive and pre-treated HIV infected patients. J. Med. Virol. 79 (2007) 207-211
37. Santos A.F., Lengruber R.B., Soares E.A., Jere A., Sprinz E., Martinez A.M., Silveira J., Sion F.S., Pathak V.K., and Soares M.A. Conservation patterns of HIV-1 RT connection and RNase H domains: Identification of new mutations in NRTI-treated patients. PLoS ONE 3 (2008) e1781
38. Sarafianos S.G., Das K., Tantillo C., Clark Jr. A.D., Ding J., Whitcomb J.M., Boyer P.L., Hughes S.H., and Arnold E. Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J. 20 (2001) 1449-1461
39. Shimura K., Kodama E., Sakagami Y., Matsuzaki Y., Watanabe W., Yamataka K., Watanabe Y., Ohata Y., Doi S., Sato M., Kano M., Ikeda S., and Matsuoka M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J. Virol. 82 (2008) 764-774
40. Ueno T., and Mitsuya H. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2′, 3′-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry 36 (1997) 1092-1099
41. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 322 (2001) 1087-1088
42. Weinstock H.S., Zaidi I., Heneine W., Bennett D., Garcia-Lerma J.G., Douglas Jr. J.M., LaLota M., Dickinson G., Schwarcz S., Torian L., Wendell D., Paul S., Goza G.A., Ruiz J., Boyett B., and Kaplan J.E. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J. Infect. Dis. 189 (2004) 2174-2180
43. Yap S.H., Sheen C.W., Fahey J., Zanin M., Tyssen D., Lima V.D., Wynhoven B., Kuiper M., Sluis-Cremer N., Harrigan P.R., and Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med. 4 (2007) e335
44. Zelina S., Sheen C.W., Radzio J., Mellors J.W., and Sluis-Cremer N. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. Antimicrob. Agents Chemother. 52 (2008) 157-163